Constellation Pharmaceuticals Selected by AlwaysOn as an OnDC Top 100 Winner

Recognized for Leading Innovation in Biotechnology

Cambridge, MA, October 8, 2009 – Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has been chosen by AlwaysOn as one of the OnDC Top 100 Winners. Inclusion in the OnDC 100 signifies major developments in the creation of new business opportunities that contribute to the renewed and continued prosperity of our country. Constellation Pharmaceuticals was specially selected by the AlwaysOn editorial team and industry experts spanning the globe based on a set of five criteria: innovation, market potential, commercialization, stakeholder value, and media buzz.

“It’s no secret that technology and innovation are vital to bringing our country out of economic recession and transforming important sectors like energy and healthcare,” said Tony Perkins, founder and CEO of AlwaysOn. “We congratulate the OnDC 100 for their success in introducing new tools, services, and systems to address the nation’s top priorities.”

“Being selected as one of the top OnDC winners is an honor that highlights Constellation’s potential to make a significant impact for patients through epigenetics, the next biological breakthrough offering promise for targeting disease above and beyond the genome,” said Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer of Constellation Pharmaceuticals. “We have built a world-class team as evidenced by the recent hiring of Ed Harlow, a leading cancer biologist, as our Chief Scientific Officer. With our strong scientific team and innovative product engine we should continue making great progress toward discovering a new class of drugs that ameliorate human disease by modulating the epigenome.”

The OnDC 100 winners were selected from among hundreds of other technology companies nominated by investors, bankers, journalists and industry insiders. The AlwaysOn editorial team conducted a rigorous three-month selection process to finalize the 2009 list.

Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated to the discovery and development of novel drugs targeting selective regulators of epigenetic function. The company raised a $32 million Series A financing and is currently building a preclinical pipeline of epigenetic drugs.

Epigenetics is an exciting new field of biology that involves chemical modifications of both DNA and of its packaging proteins (“chromatin”), which are collectively called the ‘epigenome.’ The genome, or DNA, is the “blueprint” for the human body, consisting of thousands of genes, which are the fundamental units of information necessary for normal cell growth and development. In contrast, the epigenome plays a critical role in regulating the expression of genes, that is, switching genes on or off – or in the case of disease, for switching genes on or off incorrectly. This new field of Epigenetic science provides the opportunity to create a broad new class of human therapeutics targeting selective regulators of epigenetic function.

Constellation Pharmaceuticals and the OnDC Top 100 Companies will be honored at AlwaysOn’s OnDC event on October 19th-21st at the Four Seasons Hotel in Washington DC. This two-and-a-half-day executive event features CEO presentations and high-level debates on sectors most impacted by the federal government including greentech, on-demand computing and IT security, education, and the life sciences.

A full list of all the OnDC Top 100 Winners can be found on the AlwaysOn Web site at

About Constellation
Pharmaceuticals Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science that focuses on selective regulators of gene function and expression. Constellation’s initial focus is in oncology, and the Company’s platform will also be applicable to other therapeutic areas including autoimmune, inflammatory and neurological diseases. The Company’s academic founders represent the core thought leaders in epigenetics responsible for key advances, insights and discoveries in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at

About AlwaysOn
AlwaysOn ignited the open-media revolution in early 2003 by being the first media brand to launch a global blog network. In 2004, AlwaysOn continued to lead the media industry in innovation by introducing a social network where members can connect and engage. AlwaysOn is also revolutionizing the media business by applying its open-media principles to its executive event series (Summit at Stanford, OnMedia, OnHollywood, OnDC, GoingGreen East and West, Venture Summit East and West) and quarterly print “blogozine” by empowering its members to post and share their ideas and meet each other online. As our loyal readers know, AlwaysOn is committed to the free-market, merit-driven approach to reporting and event programming. No other media brand has dared to create such open interaction with its readers and event participants.

Adriana Jenkins
For Constellation Pharmaceuticals
617 744 1713